Komori
Financial results presentation4579RaQualia Pharma Inc.Pharmaceuticals

Fiscal Year Ending December 2026 (18th Fiscal Period) First-Quarter Financial Results Briefing Materials

In Q1 FY2026, business revenue fell below the year-earlier level, while operating income, ordinary income and net income turned into losses. Meanwhile, royalty income and the overseas rollout of tegoprazan progressed, and the company explained that performance was tracking in line with its full-year plan.

Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-164
¥ millions (year-on-year change in business revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationFirst quarter of the fiscal year ending December 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥801 million-16.9%
Operating profit¥-160 million
Ordinary income¥-158 million
Net income¥-225 million
Results for the three months of the current quarter
Business profitability
¥801 million
Operating profit
¥-160 million
Ordinary income
¥-158 million
Profit attributable to owners of parent for the quarter
¥-225 million
EBITDA
¥-48 million
Full-year earnings forecast
Business profitability
¥3,980 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Business profitability20.2%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress in line with the initial plan
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Royalty income¥676 million
    Year on year against the same period last year+10.2%
  • Other income (including upfront contract fees, milestone payments and research collaboration payments)¥125 million
    Year on year against the same period last year-64.2%
New initiatives
  • Joint research in the metabolic and endocrine disease fields under the capital and business alliance with HK inno.N
  • Licensed HK inno.N to commercialize tegoprazan in Japan
  • Absorption-type merger of subsidiary テムリック
  • Rollout of the RaPPIDS platform by subsidiary ファイメクス
Key KPIsA metric the company considers important as a management benchmark.
  • Number of countries where Tegoprazan is marketed20 countries
  • Number of countries where the Tegoprazan business operates57 countries
  • K-CAB domestic sales (prescription basis)585 KRW 100 million
    Year on year against the same period last year+13.9%
  • Share of the Korean peptic ulcer drug market15 %
  • P-CAB share26.4 %
Medium-term management plan targets
Period CoveredFiscal years ending December 2026 through December 2028
Discovery research investment¥7.2 billion (over 3 years)
Preclinical and clinical development investmentUp to ¥300 million (over 3 years)
Financial targets
Equity ratio
70.5 %
Comparison with actual resultsUp 5.4 percentage points from the end of the previous fiscal year
Market Size / Share
  • Global peptic ulcer drug market¥2 1 trillion or more
  • Size of the Korean peptic ulcer drug market1,620 Hundreds of millions of yen
  • Share of the Korean peptic ulcer drug market15 %
Capital expenditures
¥3 100 million three years
Acquisition of treasury shares
Considered flexibly
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFirst quarter of the fiscal year ending December 2026
Net Sales¥801 million (YoY -16.9%)
Operating profit¥-160 million
Ordinary income¥-158 million
Net income¥-225 million
Results for the three months of the current quarterBusiness profitability ¥801 million / Operating profit ¥-160 million / Ordinary income ¥-158 million / Profit attributable to owners of parent for the quarter ¥-225 million / EBITDA ¥-48 million
Full-year earnings forecastBusiness profitability ¥3,980 million
Progress against full-year forecastBusiness profitability 20.2%
Self-assessment against the planProgress in line with the initial plan
Breakdown of Factors Affecting the ChangeFactors Royalty income / Amount ¥676 million / Year on year against the same period last year +10.2%, Factors Other income (including upfront contract fees, milestone payments and research collaboration payments) / Amount ¥125 million / Year on year against the same period last year -64.2%
Key KPIsIndicator name Number of countries where Tegoprazan is marketed / Value 20 countries / Year on year against the same period last year Not disclosed, Indicator name Number of countries where the Tegoprazan business operates / Value 57 countries / Year on year against the same period last year Not disclosed, Indicator name K-CAB domestic sales (prescription basis) / Value 585 KRW 100 million / Year on year against the same period last year +13.9%, Indicator name Share of the Korean peptic ulcer drug market / Value 15 % / Year on year against the same period last year Not disclosed, Indicator name P-CAB share / Value 26.4 % / Year on year against the same period last year Not disclosed
Medium-term management plan targetsPeriod Covered Fiscal years ending December 2026 through December 2028 / Discovery research investment ¥7.2 billion (over 3 years) / Preclinical and clinical development investment Up to ¥300 million (over 3 years)
Financial targetsEquity ratio 70.5 %
Acquisition of treasury sharesConsidered flexibly
Capital expenditures¥3 100 million (three years)
Market Size / ShareGlobal peptic ulcer drug market ¥2 1 trillion or more, Size of the Korean peptic ulcer drug market 1,620 Hundreds of millions of yen, Share of the Korean peptic ulcer drug market 15 %
New initiativesJoint research in the metabolic and endocrine disease fields under the capital and business alliance with HK inno.N, Licensed HK inno.N to commercialize tegoprazan in Japan, Absorption-type merger of subsidiary テムリック, Rollout of the RaPPIDS platform by subsidiary ファイメクス
Items this document does not state (13)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAnnual DividendPayout ratioOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The main reason for the year-on-year decline in business revenue was the absence of other income, including milestone payments and upfront contract fees. The company stated that progress was in line with its initial plan and that it intends to build up these sources of revenue toward the end of the fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Fiscal Year Ending December 2026 (18th Fiscal Period) First-Quarter Financial Results Briefing Materials | RaQualia Pharma Inc. (4579) timely disclosure | Komori